The Radiation Oncology Feed For radiation oncologists · physicists · RTTs · dosimetrists
Worth Attention radiosensitization

RT-Optimus replaces maximum tolerated dose with an optimal combination regimen

Experts propose selecting radiotherapy–drug regimens using efficacy, scheduling, late toxicity, biomarkers, and patient-reported outcomes rather than maximum tolerated dose alone.

RadOncToday · ·1 min read

KEY POINTS

  • The expert panel argues that traditional maximum-tolerated-dose designs are poorly suited to radiotherapy–drug combinations because radiation toxicities may be delayed, irreversible, tissue-specific, and missed by conventional one- to three-month dose-limiting-toxicity windows.
  • Systemic monotherapy doses may be biologically inappropriate during radiotherapy. In one NSCLC study, the tolerated olaparib dose with 66 Gy in 24 fractions was only 25 mg daily, compared with the licensed systemic dose of 300 mg twice daily.
  • The proposed endpoint is the Optimum Radiation Therapy Combination Regimen, incorporating drug dose, timing relative to each fraction, duration, number of sensitized fractions, radiotherapy dose and fractionation, and any neoadjuvant or consolidation component.
  • Trials should evaluate a biologically active dose range rather than automatically escalating until unacceptable toxicity. Drug scheduling should be explored prospectively because pre-radiotherapy, concurrent, and post-radiotherapy administration can produce different radiosensitizing, immunological, and normal-tissue effects.
  • Safety assessment should include extended follow-up, clinician-graded acute and late toxicity, patient-reported outcomes, and patient-defined acceptable toxicity thresholds. Potential early safety biomarkers include tissue-specific proteins and circulating methylated DNA.
  • Intermediate efficacy measures such as circulating tumour DNA clearance, proof-of-mechanism assays, pharmacokinetic–pharmacodynamic analyses, and longitudinal radiomics may help distinguish active regimens before local-control or survival data mature.
  • Suggested statistical approaches include backfilling previously explored doses, randomized expansion between active dose levels, adaptive platform trials, and inclusion of a contemporaneous radiotherapy-alone calibration cohort.
  • The framework is conceptual. Most proposed biomarkers remain incompletely validated, longer safety windows increase trial duration and cost, and randomization to lower doses or radiotherapy alone may be difficult in curative settings.

CLINICAL TAKEAWAY

The highest tolerable drug dose is not necessarily the best dose to combine with radiotherapy. Early trials should optimize the entire regimen around biological activity and the therapeutic index, but RT-Optimus must still demonstrate that this additional complexity produces more reliable phase II and III decisions.

SOURCE

International Journal of Radiation Oncology, Biology, Physics